Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Decision Has Plan B Headed For Behind-The-Counter Sale

18 Apr 2005

• By The Tan Sheet

FDA appears to be ready to create a third class of drugs

Related Content

FDA Confirmation Process Hits A Roadblock: Time For Plan B?

18 Apr 2005

Plan B Behind-The-Counter Status Discouraged By Panel Members

22 Dec 2003

FDA OTC Head Ganley Talks Third Class, Plan B And Drug Switches

01 Jan 2005

Additional Topics

OTC Drugs Consumer

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.